Literature DB >> 26818109

Fibroblast-Mediated Collagen Remodeling Within the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by BrafV600E and Pten Loss.

Lee Ann Jolly1, Sergey Novitskiy2, Phillip Owens2, Nicole Massoll3, Nikki Cheng4, Wei Fang4, Harold L Moses2, Aime T Franco5.   

Abstract

Contributions of the tumor microenvironment (TME) to progression in thyroid cancer are largely unexplored and may illuminate a basis for understanding rarer aggressive cases of this disease. In this study, we investigated the relationship between the TME and thyroid cancer progression in a mouse model where thyroid-specific expression of oncogenic BRAF and loss of Pten (Braf(V600E)/Pten(-/-)/TPO-Cre) leads to papillary thyroid cancers (PTC) that rapidly progress to poorly differentiated thyroid cancer (PDTC). We found that fibroblasts were recruited to the TME of Braf(V600E)/Pten(-/-)/TPO-Cre thyroid tumors. Conditioned media from cell lines established from these tumors, but not tumors driven by mutant H-ras, induced fibroblast migration and proliferation in vitro Notably, the extracellular matrix of Braf(V600E)/Pten(-/-)/TPO-Cre tumors was enriched with stromal-derived fibrillar collagen, compared with wild-type or Hras-driven tumors. Further, type I collagen enhanced the motility of Braf(V600E)/Pten(-/-)/TPO-Cre tumor cells in vitro In clinical specimens, we found COL1A1 and LOX to be upregulated in PTC and expressed at highest levels in PDTC and anaplastic thyroid cancer. Additionally, increased expression levels of COL1A1 and LOX were associated with decreased survival in thyroid cancer patients. Overall, our results identified fibroblast recruitment and remodeling of the extracellular matrix as pivotal features of the TME in promoting thyroid cancer progression, illuminating candidate therapeutic targets and biomarkers in advanced forms of this malignancy. Cancer Res; 76(7); 1804-13. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26818109      PMCID: PMC4873339          DOI: 10.1158/0008-5472.CAN-15-2351

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake.

Authors:  Markus Loeffler; Jörg A Krüger; Andreas G Niethammer; Ralph A Reisfeld
Journal:  J Clin Invest       Date:  2006-06-22       Impact factor: 14.808

2.  Promotion of tumor cell migration by extracellular matrix proteins in human pancreatic cancer.

Authors:  Eduard Ryschich; Akmal Khamidjanov; Vachtang Kerkadze; Markus W Büchler; Margot Zöller; Jan Schmidt
Journal:  Pancreas       Date:  2009-10       Impact factor: 3.327

3.  Matrix crosslinking forces tumor progression by enhancing integrin signaling.

Authors:  Kandice R Levental; Hongmei Yu; Laura Kass; Johnathon N Lakins; Mikala Egeblad; Janine T Erler; Sheri F T Fong; Katalin Csiszar; Amato Giaccia; Wolfgang Weninger; Mitsuo Yamauchi; David L Gasser; Valerie M Weaver
Journal:  Cell       Date:  2009-11-25       Impact factor: 41.582

4.  Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo.

Authors:  Kelly A Miller; Nicole Yeager; Kristen Baker; Xiao-Hui Liao; Samuel Refetoff; Antonio Di Cristofano
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

Review 5.  Cancer and the tumor microenvironment: a review of an essential relationship.

Authors:  Flaubert Mbeunkui; Donald J Johann
Journal:  Cancer Chemother Pharmacol       Date:  2008-12-14       Impact factor: 3.333

6.  Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.

Authors:  Zhi Liu; Peng Hou; Meiju Ji; Haixia Guan; Kimberly Studeman; Kirk Jensen; Vasily Vasko; Adel K El-Naggar; Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2008-05-20       Impact factor: 5.958

Review 7.  BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.

Authors:  Mingzhao Xing
Journal:  Endocr Rev       Date:  2007-10-16       Impact factor: 19.871

8.  Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.

Authors:  Julio C Ricarte-Filho; Mabel Ryder; Dhananjay A Chitale; Michael Rivera; Adriana Heguy; Marc Ladanyi; Manickam Janakiraman; David Solit; Jeffrey A Knauf; R Michael Tuttle; Ronald A Ghossein; James A Fagin
Journal:  Cancer Res       Date:  2009-06-01       Impact factor: 12.701

9.  Collagen density promotes mammary tumor initiation and progression.

Authors:  Paolo P Provenzano; David R Inman; Kevin W Eliceiri; Justin G Knittel; Long Yan; Curtis T Rueden; John G White; Patricia J Keely
Journal:  BMC Med       Date:  2008-04-28       Impact factor: 8.775

Review 10.  Migratory neighbors and distant invaders: tumor-associated niche cells.

Authors:  Jared Wels; Rosandra N Kaplan; Shahin Rafii; David Lyden
Journal:  Genes Dev       Date:  2008-03-01       Impact factor: 11.361

View more
  37 in total

1.  Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness.

Authors:  Myriem Boufraqech; Dhaval Patel; Naris Nilubol; Astin Powers; Timothy King; Jasmine Shell; Justin Lack; Lisa Zhang; Sudheer Kumar Gara; Viswanath Gunda; Joanna Klubo-Gwiezdzinska; Suresh Kumar; James Fagin; Jeffrey Knauf; Sareh Parangi; David Venzon; Martha Quezado; Electron Kebebew
Journal:  Thyroid       Date:  2018-12-28       Impact factor: 6.568

Review 2.  Feeling Things Out: Bidirectional Signaling of the Cell-ECM Interface, Implications in the Mechanobiology of Cell Spreading, Migration, Proliferation, and Differentiation.

Authors:  Andrew E Miller; Ping Hu; Thomas H Barker
Journal:  Adv Healthc Mater       Date:  2020-02-09       Impact factor: 9.933

3.  Myeloid Cell-Derived TGFβ Signaling Regulates ECM Deposition in Mammary Carcinoma via Adenosine-Dependent Mechanisms.

Authors:  Georgii Vasiukov; Tatiana Novitskaya; Andries Zijlstra; Philip Owens; Fei Ye; Zhiguo Zhao; Harold L Moses; Timothy Blackwell; Igor Feoktistov; Sergey V Novitskiy
Journal:  Cancer Res       Date:  2020-04-20       Impact factor: 12.701

4.  Structural alterations in tumor-draining lymph nodes before papillary thyroid carcinoma metastasis.

Authors:  Andrew M Hinson; Nicole A Massoll; Lee Ann Jolly; Brendan C Stack; Donald L Bodenner; Aime T Franco
Journal:  Head Neck       Date:  2017-05-03       Impact factor: 3.147

5.  Multiscale Modelling of Fibres Dynamics and Cell Adhesion within Moving Boundary Cancer Invasion.

Authors:  Robyn Shuttleworth; Dumitru Trucu
Journal:  Bull Math Biol       Date:  2019-04-12       Impact factor: 1.758

6.  Identification of gene co-expression modules and hub genes associated with lymph node metastasis of papillary thyroid cancer.

Authors:  Tianyu Zhai; Dilidaer Muhanhali; Xi Jia; Zhiyong Wu; Zhenqin Cai; Yan Ling
Journal:  Endocrine       Date:  2019-07-22       Impact factor: 3.633

Review 7.  Immunotherapy for advanced thyroid cancers - rationale, current advances and future strategies.

Authors:  Jena D French
Journal:  Nat Rev Endocrinol       Date:  2020-08-24       Impact factor: 43.330

8.  Immune Suppression Mediated by Myeloid and Lymphoid Derived Immune Cells in the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by HrasG12V and Pten Loss.

Authors:  Lee Ann Jolly; Nicole Massoll; Aime T Franco
Journal:  J Clin Cell Immunol       Date:  2016-09-16

Review 9.  Progression and dormancy in metastatic thyroid cancer: concepts and clinical implications.

Authors:  Neel Rajan; Tilak Khanal; Matthew D Ringel
Journal:  Endocrine       Date:  2020-08-11       Impact factor: 3.633

Review 10.  The Thyroid Tumor Microenvironment: Potential Targets for Therapeutic Intervention and Prognostication.

Authors:  Laura MacDonald; Jonathan Jenkins; Grace Purvis; Joshua Lee; Aime T Franco
Journal:  Horm Cancer       Date:  2020-06-17       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.